Bosheng Medical Receives Further Recognition: Guideline Co-Authored by the Company Included in Chinese Pharmacopoeia (2025 Edition)

2026-03-25

字号

Bosheng Medical Receives Further Recognition: Guideline Co-Authored by the Company Included in Chinese Pharmacopoeia (2025 Edition)

The Guideline for Rubber Seals for Pharmaceutical Packaging, co-authored by Jiangsu Bosheng Medical New Materials Co., Ltd., has been included in the 2025 edition of the Pharmacopoeia of the People’s Republic of China (Ch.P). As the only pharmaceutical packaging materials company in China involved in drafting this guideline, the inclusion marks full recognition of Bosheng Medical’s capabilities in R&D, manufacturing, and quality control of pharmaceutical packaging materials.

In addition to the Guideline for Rubber Seals for Pharmaceutical Packaging, the company also participated—uniquely as an enterprise—in the formulation of two general chapters, namely the General Provisions for Rubber Seals for Pharmaceutical Packaging, as well as five method standards, including the Determination of Ash in Rubber Seals and the Determination of Water in Rubber Seals.

As a critical component of pharmaceuticals, packaging materials accompany drugs throughout production, distribution, and use. Their quality directly affects drug safety and efficacy, and ultimately public health. As a member of the Medicinal Rubber Closure Professional Committee of the China Pharmaceutical Packaging Association and a leading player in the domestic pharmaceutical packaging industry, Bosheng Medical continues to focus on the development of key technologies for pharmaceutical packaging materials and the pharmaceutical sector. The company actively aligns with international standards, has led or participated in the formulation of multiple national and industry standards, and holds over 100 authorized patents, contributing significantly to the advancement of standards in the pharmaceutical packaging materials industry.

In recent years, Bosheng Medical has pursued an innovation-driven strategy, leveraging the synergies between its “one institute and two business units.” The company focuses on the R&D and manufacturing of new pharma packaging materials, continuously advancing product development and technological upgrades. Its product portfolio—covering rubber stoppers, infusion films, and more—features internal control standards that comprehensively exceed national and industry benchmarks. Some products have been developed as domestic alternatives to imports. The company is committed to becoming a leading provider of products and solutions in the pharmaceutical packaging sector.

The Ch.P serves as the national drug standard and is the statutory basis for drug R&D, production, distribution, use, and regulatory oversight. According to a recent announcement by the National Medical Products Administration, the 2025 edition of the Chinese Pharmacopoeia was approved by the Executive Committee of the 12th Pharmacopoeia Commission and will take effect on October 1, 2025.

关键词: